The
phosphatidylinositol 3-kinase (PI3 K)/Akt/
mammalian target of rapamycin (mTOR) signaling axis plays a central role in cell proliferation, growth and survival under physiological conditions. However, aberrant PI3 K/Akt/mTOR signaling has been implicated in many human
cancers, including human
triple negative breast cancer. Therefore, dual inhibitors of PI3 K/Akt and mTOR signaling could be valuable agents for treating
breast cancer. The objective of this study was to investigate the effect of
piperlongumine (PPLGM), a natural
alkaloid on PI3 K/Akt/mTOR signaling, Akt mediated regulation of
NF-kB and apoptosis evasion in human
breast cancer cells. Using molecular docking studies, we found that PPLGM physically interacts with the conserved domain of PI3 K and mTOR
kinases and the results were comparable with standard dual inhibitor PF04691502. Our results demonstrated that treatment of different human
triple-negative breast cancer cells with PPLGM resulted in concentration- and time-dependent growth inhibition. The inhibition of
cancer cell growth was associated with G1-phase cell cycle arrest and down-regulation of the
NF-kB pathway leads to activation of the mitochondrial apoptotic pathway. It was also found that PPLGM significantly decreased the expression of p-Akt,
p70S6K1, 4E-BP1,
cyclin D1, Bcl-2, p53 and increased expression of Bax,
cytochrome c in human
triple-negative breast cancer cells. Although
insulin treatment increased the phosphorylation of Akt (Ser473),
p70S6K1, 4E-BP1, PPLGM abolished the
insulin mediated phosphorylation, it clearly indicates that PPLGM acts through PI3 k/Akt/mTOR axis. Our results suggest that PPLGM may be an effective therapeutic agent for the treatment of human
triple negative breast cancer.